atorvastatin has been researched along with osteoprotegerin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Blaschke, S; Emons, G; Frosch, KH; Gründker, C; Hofbauer, LC; Schoppet, M; Viereck, V | 1 |
| Bandios, S; Fotiadis, G; Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Katinios, A; Kougias, P; Liapis, CD; Moumtzouoglou, A; Sailer, N; Vitta, I; Voliotis, K | 1 |
| Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Liapis, CD; Moumtzouoglou, A; Sailer, N | 1 |
| Avgerinos, ED; Gerasimidis, T; Kadoglou, NP; Kakisis, JD; Kapelouzou, A; Karayannacos, PE; Liapis, CD; Moumtzouoglou, A | 1 |
| Dimitrow, PP; Gackowski, A; Jawień, M | 1 |
| Dean, IN; Rawal, SY; Stein, SH; Tipton, DA | 1 |
| Gradosova, I; Palicka, V; Svejkovska, K; Tichy, A; Zivna, H; Zivny, P | 1 |
| Arnal, JF; Lucanus, E; Nickenig, G; Pelster, B; Steinmetz, M; Werner, N | 1 |
| Baretton, GB; Bauer, T; Benad-Mehner, P; Bornhäuser, M; Ebert, R; Göbel, A; Hadji, P; Hofbauer, LC; Jakob, F; Muders, MH; Rachner, TD; Rauner, M; Schem, C; Thiele, S | 1 |
| Bauer, I; Bertolotto, M; Dallegri, F; Fabre, M; Galan, K; Lenglet, S; Mach, F; Montecucco, F; Nencioni, A; Palombo, D; Pane, B; Pelli, G; Pende, A; Python, M; Quercioli, A; Spinella, G; Vuilleumier, N | 1 |
| Agha, A; Ashley, DT; Davenport, C; McHenry, CM; O'Gorman, DJ; O'Sullivan, EP; Smith, D; Thompson, CJ | 1 |
| Bertacco, E; Buso, R; Di Virgilio, R; Fadini, GP; Faggin, E; Palmosi, T; Pauletto, P; Plebani, M; Puato, M; Rattazzi, M; Zaninotto, M | 1 |
| Cui, W; Du, H; Hao, J; Liu, D; Liu, F; Lu, J; Yang, X | 1 |
| Baloch, Z; Huo, Q; Ma, T; Shi, Q; Xie, Y; Zhou, H | 1 |
| Dolci, GS; Medeiros Fossati, AC; Onofre de Souza, D; Portela, LV | 1 |
| Gao, Y; Wang, T; Zhao, Y | 1 |
5 trial(s) available for atorvastatin and osteoprotegerin
| Article | Year |
|---|---|
Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis.
Topics: Aged; Atorvastatin; Biomarkers; Blood Pressure; C-Reactive Protein; Calcinosis; Carotid Stenosis; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Count; Male; Middle Aged; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography | 2008 |
Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Stenosis; Cerebrovascular Disorders; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2010 |
The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Biomarkers; Calcinosis; Down-Regulation; Drug Administration Schedule; Echocardiography, Doppler; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteopontin; Osteoprotegerin; Poland; Pyrroles; RANK Ligand; Sclerosis; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteoprotegerin; Pulse Wave Analysis; Treatment Outcome; Vascular Stiffness | 2015 |
Atorvastatin Reduces Circulating Osteoprogenitor Cells and T-Cell RANKL Expression in Osteoporotic Women: Implications for the Bone-Vascular Axis.
Topics: Aged; Atorvastatin; Biomarkers; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Jurkat Cells; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Stem Cells; T-Lymphocytes; Time Factors; Treatment Outcome | 2016 |
11 other study(ies) available for atorvastatin and osteoprotegerin
| Article | Year |
|---|---|
Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts.
Topics: Adult; Atorvastatin; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Glucocorticoids; Glycoproteins; Heptanoic Acids; Humans; Male; Mevalonic Acid; Models, Biological; Osteoblasts; Osteoprotegerin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2005 |
Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis.
Topics: Aged; Angioplasty; Atorvastatin; Biomarkers; C-Reactive Protein; Calcinosis; Carotid Stenosis; Combined Modality Therapy; Down-Regulation; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2010 |
Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts.
Topics: Atorvastatin; Cell Culture Techniques; Cell Survival; Cells, Cultured; Coloring Agents; Culture Media, Serum-Free; Fibroblasts; Gingiva; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Osteoprotegerin; Pyrroles; RANK Ligand; Simvastatin; Temperature; Tetrazolium Salts; Thiazoles; Time Factors | 2011 |
The role of atorvastatin in bone metabolism in male albino Wistar rats.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Animals; Atorvastatin; Biomarkers; Biomechanical Phenomena; Blotting, Western; Bone and Bones; Bone Density; Bone Morphogenetic Protein 2; Collagen Type I; Electrophoresis, Polyacrylamide Gel; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteocalcin; Osteoprotegerin; Peptide Fragments; Procollagen; Protein Prenylation; Pyrroles; Rats; Rats, Wistar | 2011 |
Atorvastatin-induced increase in progenitor cell levels is rather caused by enhanced receptor activator of NF-kappaB ligand (RANKL) cell proliferation than by bone marrow mobilization.
Topics: Animals; Antigens, Ly; Atorvastatin; Bone Marrow; Cell Proliferation; Fibroblast Growth Factor 2; Heptanoic Acids; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Physiologic; Osteoprotegerin; Perfusion; Pyrroles; RANK Ligand; Re-Epithelialization; Stem Cells; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density Conservation Agents; Bone Neoplasms; cdc42 GTP-Binding Protein; Cell Line, Tumor; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; L Cells; Lymphocyte Activation; MCF-7 Cells; Mevalonic Acid; Mice; Osteoblasts; Osteogenesis; Osteoprotegerin; Prenylation; Pyrroles; Rho Factor; RNA Interference; RNA, Small Interfering; Triple Negative Breast Neoplasms; Wnt3A Protein; Zoledronic Acid | 2014 |
Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Stenosis; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Neutrophil Activation; Neutrophils; NF-kappa B; Osteopontin; Osteoprotegerin; Pyrimidines; Pyrroles; RANK Ligand; Risk Factors; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Cardiomegaly; Cross-Sectional Studies; Disease Models, Animal; Gene Expression Profiling; Hydroxyproline; Hypertension; Immunohistochemistry; Male; Myocardium; NF-kappa B; Osteoprotegerin; RANK Ligand; Rats, Inbred SHR; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Ventricular Function, Left | 2016 |
The effect of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA), on the prevention of osteoporosis in ovariectomized rabbits.
Topics: Animals; Atorvastatin; Bone Density; Cell Line; Female; Femur; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imaging, Three-Dimensional; Lumbar Vertebrae; Mice; Osteoporosis; Osteoprotegerin; Ovariectomy; Rabbits; RANK Ligand | 2017 |
Atorvastatin-induced osteoclast inhibition reduces orthodontic relapse.
Topics: Animals; Atorvastatin; Bone Remodeling; Femur; Immunohistochemistry; Male; Maxilla; Osteoclasts; Osteoprotegerin; RANK Ligand; Rats; Rats, Wistar; Recurrence; Tooth Mobility; Tooth Movement Techniques | 2017 |
The Impact of Atorvastatin on RANKL Expression in Rats during the Retention Stage after Orthodontic Tooth Movement.
Topics: Animals; Atorvastatin; Maxilla; Osteoprotegerin; Rats; Tooth; Tooth Movement Techniques | 2022 |